SpyGlass Pharma Inc. (SGP)
NASDAQ: SGPHealth CareMedical/Dental InstrumentsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
SGP stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.02B
- EPS (TTM)
- -$2.70
- Dividend yield
- None
- 52-week range
- 17.06 – 39.92
- Day range
- 29.60 – 31.73
- Volume / Avg
- 108.91K / 114.63K
- Beta
- —
- Shares outstanding
- 33.46M
52-week range
SGP stock today
On Nov 20, SGP ended the session at $30.43, shedding $0.35 (1.14%), versus the S&P 500's 3.70% decline. At this level, SGP sits in the middle of its 52-week range of $17.06 to $39.92: 23.8% below the high, set on Nov 9, 2026 and 78.4% above the low. SpyGlass Pharma has posted a net loss over the last twelve months (EPS of -$2.70), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About SpyGlass Pharma
Company profileSpyGlass Pharma, Inc. operates as a biopharmaceutical company that provides treatment and drug delivery for patients living with chronic eye conditions. The company develops the Bimatoprost Drug Pad-IOL System (BIM-IOL System), including novel and proprietary drug pads attached to an intraocular lens (IOL), which is designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) in patients.
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- CEO
- Mr. Patrick H. Mooney
- Headquarters
- Irvine, CA
- Employees
- 88
- IPO year
- 2026
- Website
- spyglasspharma.com
Financial highlights
Full financialsSpyGlass Pharma reported a net loss of $39.9 million, compared with a loss of $29.2 million a year earlier. Diluted earnings per share came in at -$17.98.
| Fiscal year | FY 2025 | FY 2024 |
|---|---|---|
| Revenue | — | — |
| Growth | — | — |
| Net income | $-39.87M | $-29.16M |
| EPS (diluted) | $-17.98 | $-16.31 |
Analyst forecast
ForecastConsensus (6 analysts)
strong_buy
Avg. price target
$46.67+53.37%
- Strong buy 1
- Buy 5
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 11, 2026
- EPS actual vs est.
- $-0.73 vs $-0.66
- Surprise
- -10.61%
SGP news
All SGP news- SpyGlass Pharma Q3 Loss WidensNasdaq
- SpyGlass Pharma, Inc. GAAP EPS of -$0.73 misses by $0.09Seeking Alpha
- SpyGlass Pharma Reports Third Quarter 2026 Financial Results and Provides Corporate UpdatesGlobeNewswire
- SpyGlass Pharma Announces Positive 4-Year Data From First-in-Human Trial of Its Innovative BIM-IOL SystemGlobeNewswire
SpyGlass Pharma peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| IARTIntegra LifeSciences Holdings Corporation | 13.25 | -2.21% | $1.03B | vs SGP |
| ATECAlphatec Holdings Inc. | 6.68 | -3.19% | $1.02B | vs SGP |
| IRMDiRadimed Corporation | 81.02 | -0.30% | $1.04B | vs SGP |
| SIBNSI-BONE Inc. | 23.73 | -0.08% | $1.07B | vs SGP |
| DRTSAlpha Tau Medical Ltd. | 11.76 | +3.93% | $1.09B | vs SGP |
| AORTArtivion Inc. | 18.16 | -2.00% | $886.02M | vs SGP |
| TNDMTandem Diabetes Care Inc. | 17.46 | +3.93% | $1.22B | vs SGP |
| KIDSOrthoPediatrics Corp. | 31.74 | -2.37% | $828.75M | vs SGP |
Indexes, lists and sector
SpyGlass Pharma stock FAQ
What is SpyGlass Pharma's stock price today?
SGP last traded at $30.43 as of Nov 20, 4:00 PM EST, down 1.14% on the day. Prices are delayed at least 15 minutes.
Who is SpyGlass Pharma's CEO?
Mr. Patrick H. Mooney is the chief executive officer of SpyGlass Pharma Inc., which has about 88 employees.
What is the SGP 52-week high?
The 52-week high for SGP is $39.92 and the 52-week low is $17.06. The stock is currently 23.8% below its high.